Personalized Friedreich Ataxia Treatment and Prediction System
Legal Citation
Summary of the Inventive Concept
A synergistic combination of TfR1 palmitoylation-increasing drugs, wearable devices, blockchain-based platforms, AI-powered predictive models, and IoT-enabled devices to provide personalized treatment plans and optimize therapeutic responses for Friedreich ataxia patients.
Background and Problem Solved
Friedreich ataxia is a debilitating degenerative disease with limited treatment options. The original patent disclosed methods of treating and predicting therapeutic responses in Friedreich ataxia patients using TfR1 palmitoylation-increasing drugs. However, these methods have limitations in terms of personalized treatment and data management. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful system.
Detailed Description of the Inventive Concept
The system comprises a wearable device that monitors a patient's gait and limb ataxia, a blockchain-based platform that securely stores and analyzes the patient's health data, and an AI-powered predictive model that forecasts therapeutic responses to TfR1 palmitoylation-increasing drugs. The platform is integrated with an IoT-enabled device that monitors and adjusts the patient's environment to optimize the therapeutic response. The system provides a personalized treatment plan based on the analysis of the patient's health data and forecasts therapeutic responses.
Novelty and Inventive Step
The new inventive concept introduces a synergistic combination of TfR1 palmitoylation-increasing drugs, wearable devices, blockchain-based platforms, AI-powered predictive models, and IoT-enabled devices, which is not obvious from the original patent. The integration of these distinct technologies provides a novel and non-obvious solution for personalized treatment and prediction of therapeutic responses in Friedreich ataxia patients.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different types of wearable devices, such as implantable sensors or mobile applications, or the integration of additional technologies, such as machine learning algorithms or natural language processing. Variations of the system could be designed for different types of degenerative diseases or patient populations.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the healthcare industry, particularly in the areas of personalized medicine and digital health. The system could be marketed to pharmaceutical companies, healthcare providers, and patients suffering from Friedreich ataxia and other degenerative diseases.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical biotechnology, specifically neurodegenerative disease treatment, personalized medicine, and digital health technologies with expertise in pharmaceutical interventions, patient monitoring systems, and predictive health modeling
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in biomedical engineering, medical informatics, or clinical research, possessing knowledge of neurodegenerative disease treatment, digital health technologies, data analytics, and personalized medicine approaches
Obviousness Rationale
A PHOSITA would recognize that integrating digital monitoring technologies with pharmaceutical interventions for neurodegenerative diseases represents a predictable and logical extension of existing personalized medicine approaches. The combination of wearable sensors, AI predictive modeling, and targeted drug therapies follows established paradigms in precision healthcare. The technical elements disclosed in the PTD represent incremental improvements that would be obvious to a skilled practitioner seeking to optimize treatment monitoring and response prediction.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,532 |
|---|---|
| Title | Treatment and prediction of therapeutic responses in patients suffering from Friedreich ataxia |
| Assignee(s) | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), The Assistance Publique—Hôpitaux de Paris (APHP), FONDATION IMAGINE |